Corticosteroids In The Treatment Of Dengue Shoc...

Cerebral Responses To Innocuous Somatic Pressur...

Ultrasonic Dissection And Coagulation

Pharmacogenomic Knowledge And Resource Needs Am...

Critical Appraisal And Data Extraction For Syst...

0 votes
Managing Cardiovascular Disease Risk In Antipsychotics
Author: Matisyahu Shulman, Avraham Miller, Jason Misher, Aleksey Tentler
13 pages
One time payment: €0.00
Required subscription: Free
Type of publication: Article
ISBN/ISSN: 1178-2390
DOI: 10.2147/49817
Follow this publisher

Share this publication:


Background: The use of antipsychotic medication in the United States and throughout the world has greatly increased over the last fifteen years. These drugs have significant side effect burdens, many of them relating to cardiovascular health.

Objective: To review the available evidence on the major cardiovascular issues that arise in patients taking antipsychotic medication.

Method: A PubMed literature review was performed to identify recent meta-analyses, review articles, and large studies. Further articles were identified through cited papers and based on expert consultation when necessary.

Results: Clinical guidance on the following adverse effects and antipsychotics was reviewed: electrocardiogram (ECG) changes, (specifically, prolonged QT and risk of torsades de pointes), weight gain, dyslipidemia, metabolic syndrome, and myocarditis. Specific attention was paid to monitoring guidelines and treatment options in the event of adverse events, including dose change, medication switch, or adjuvant therapy.

Select a payment method